Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003123375 | SCV003800682 | likely pathogenic | Deficiency of hydroxymethylglutaryl-CoA lyase | 2023-01-06 | criteria provided, single submitter | clinical testing | Variant summary: The variant identified by MLPA or other technology involves the deletion of exon 2 in the HMGCL gene. A presumed nomenclature of c.(60+1_61-1)_(144+1_145-1)del has been designated for the purposes of this classification. Although exact breakpoints of this CNV are not known, it is expected to result in a large in-frame deletion change in the HMGCL gene, a known mechanism of disease. The variant was absent in 20278 control chromosomes (gnomAD, Structural Variants dataset). Skipping of exon 2 at the RNA level has been reported in the literature in an individual affected with HMG-CoA Lyase Deficiency (Grunert_2017). No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely pathogenic. |